NMN and Heart Health: What Cardiovascular Research Shows About NAD+

The intersection of NMN and cardiovascular health has drawn increasing scientific attention as research continues to clarify the central role of NAD⁺ in maintaining vascular function, energy metabolism, and cellular repair. While most human studies to date are still in early stages, a growing body of preclinical work and several small, carefully conducted clinical trials point toward a potential for nicotinamide mononucleotide to support the aging cardiovascular system — though direct heart-outcome data remain absent.

The Research Landscape for NMN and Cardiovascular Health

Almost all direct evidence linking NMN to cardiovascular improvement comes from animal models, with human research still centered on metabolic and safety endpoints rather than hard cardiovascular events. The landmark preclinical study by Mills et al. (2016) demonstrated that long‑term NMN administration in aged mice restored NAD⁺ levels in multiple tissues, reversed age‑related declines in capillary density, and preserved arterial elasticity. These vascular benefits were accompanied by increases in SIRT1 activity, a NAD⁺‑dependent enzyme that regulates endothelial function and mitochondrial health. While the findings were striking, they were obtained in a species whose cardiovascular aging timeline is vastly compressed, and the doses used (equivalent to several hundred milligrams per kilogram body weight) far exceed typical human supplementation.

In humans, the three most frequently cited placebo‑controlled trials — Yoshino et al. (2021), Igarashi et al. (2022), and Fukamizu et al. (2022) — all focused on NMN’s safety, bioavailability, and its ability to raise blood NAD⁺ concentrations. None of these studies directly measured changes in blood pressure, endothelial function, arterial stiffness, or incidence of cardiovascular events. The field is evolving quickly, and for a broader overview of what the newest human research says about NMN, see our article on NMN supplements in 2026. Currently, the connection between NMN and cardiovascular health in humans must therefore be drawn through mechanistic reasoning and surrogate markers, not outcome data. This is the essential caveat that every discussion of the topic must acknowledge.

The Mechanism: How NMN Supports Cardiovascular Function

To understand why NMN might matter for the heart and blood vessels, one must start with NAD⁺ (nicotinamide adenine dinucleotide). This coenzyme is indispensable for both redox reactions — shuttling electrons in mitochondrial respiration — and as a substrate for several classes of signaling enzymes, most notably the sirtuins (SIRT1‑7) and poly(ADP‑ribose) polymerases (PARPs). Inside the cardiovascular system, SIRT1 in endothelial cells deacetylates and activates endothelial nitric oxide synthase (eNOS), increasing production of nitric oxide, the master vasodilator that keeps arteries supple, reduces inflammation, and inhibits platelet aggregation. SIRT1 also promotes mitochondrial biogenesis in cardiomyocytes, ensuring the heart’s immense energy demands are met. NAD⁺ is equally critical for PARP‑mediated DNA repair, which protects vascular smooth muscle cells against senescence and the pro‑inflammatory secretory phenotype that drives arterial stiffening.

NAD⁺ levels decline with age in most human tissues, a phenomenon now recognized as one of the 9 hallmarks of cellular aging. This decline is partly due to reduced activity of the salvage enzyme NAMPT, which recycles nicotinamide to NMN, the immediate precursor of NAD⁺ (Garten et al., 2015). By providing NMN orally, the logic goes, one can bypass the age‑related bottleneck in the NAMPT pathway and replenish cellular NAD⁺ pools. In mice, Mills et al. (2016) showed that this strategy directly translated into better vascular function: old animals receiving NMN exhibited gene expression patterns in their aortas that resembled those of young mice, along with improved capillary density in skeletal muscle and brain — tissues critical for systemic cardiovascular resilience. While the human relevance of these findings is biologically plausible, the leap from mouse aorta to human coronary artery requires confirmation in controlled trials.

Human NMN Trials: Dosing, Safety, and Markers for Cardiovascular Health

The existing human literature provides a foundation for safety and dosing but leaves the cardiovascular question open. All three published randomized, placebo‑controlled trials examined oral NMN at 250 mg per day — a dose now widely used in supplements — and none reported serious adverse effects. The table below summarizes the key studies and what they can (and cannot) tell us about NMN and cardiovascular health.

Study	Population	NMN Dose & Duration	Key Findings	Relevance to Cardiovascular Health
Yoshino et al. (2021)	25 postmenopausal women with prediabetes	250 mg/day for 10 weeks	Increased muscle insulin sensitivity by ~18%; raised plasma NAD+ metabolites; no adverse effects	Insulin resistance is a major driver of cardiovascular disease; improvement suggests indirect cardiometabolic benefit
Igarashi et al. (2022)	30 healthy adults (aged 20–65) with mild sleep disturbance	250 mg/day for 12 weeks	Significantly elevated whole‑blood NAD+ levels (p<0.01); improved sleep quality; safe	NAD+ repletion is a prerequisite for vascular benefits, but no CV endpoints measured
Fukamizu et al. (2022)	30 healthy Japanese men (aged 40–60)	250 mg/day for 12 weeks	Robustly increased blood NAD+ and nicotinamide metabolite levels; safe and well‑tolerated	Confirms oral NMN bioavailability in middle‑aged adults; provides no direct vascular data

On the positive side, these trials confirm that 250 mg of oral NMN can raise systemic NAD⁺ concentrations in middle‑aged and older adults — a necessary first step if one hopes to replicate the preclinical cardiovascular benefits. The effect on insulin sensitivity seen in Yoshino et al. (2021) is particularly noteworthy because insulin‑resistant states accelerate vascular aging, endothelial dysfunction, and atherosclerosis. Yet no trial to date has enrolled participants with known cardiovascular disease or tracked endpoints such as flow‑mediated dilation, pulse wave velocity, or cardiac output. Therefore, while the biomarker data are encouraging, they remain surrogate rather than conclusive.

Who Benefits Most from NMN for Cardiovascular Support?

Extrapolating from both mouse and human data, the populations most likely to derive cardiovascular benefit from NMN are those in whom NAD⁺ deficiency is already present: older adults, individuals with metabolic syndrome, and possibly those with vascular aging beyond what is expected for chronological age. The Mills et al. (2016) study was clear on this point — young mice did not show the same magnitude of vascular improvement, implying that NMN primarily restores what has been lost rather than supercharging a system that is already NAD⁺‑replete. In humans, the participants in the Yoshino trial were postmenopausal women with prediabetes, a group at significantly elevated risk for future cardiovascular events; the metabolic improvement they experienced suggests that NMN may be especially relevant when glucose handling has begun to falter.

That said, it would be premature to recommend NMN as a therapy for diagnosed cardiovascular disease. The evidence for lowering blood pressure or reversing arterial stiffness is confined to animal work. Anyone managing hypertension, for example, should first rely on interventions with robust human data — including sodium reduction, exercise, and supplements where appropriate. For those looking at adjunctive approaches, magnesium has a well‑documented relationship with blood pressure regulation that is supported by numerous meta‑analyses. NMN’s role, at present, is better viewed as a potential longevity‑support tool that may, over time, help maintain vascular resilience as part of a broader strategy against the age‑related decline in NAD+.

Using NMN for Cardiovascular Health: Practical Takeaways

• Dose from human studies: The best‑studied dose is 250 mg per day. Higher doses up to 500 mg are often used in later research and in commercial products, and they appear safe, but long‑term safety data beyond 12 weeks are limited.
• Don’t expect immediate cardiovascular effects: NMN works by gradually restoring systemic NAD⁺ pools and influencing gene expression through sirtuins. It is not a vasodilator that acts within hours.
• Combine with exercise: Regular aerobic activity naturally boosts NAD⁺ and activates the same sirtuin pathways that NMN targets. The synergy may be more powerful than either intervention alone.
• Address other risk factors first: Because direct heart‑outcome data are absent, prioritize evidence‑based measures like blood pressure control. If blood pressure reduction is a primary goal, a supplement such as magnesium — which has clear human trial support — may be a more appropriate starting point.
• Realistic expectations: The connection between NMN and cardiovascular health is built on strong mechanism and compelling animal data, but human confirmation is still pending. Clinicians and consumers should view NMN as a preventive supplement, not a treatment.
• Quality matters: If incorporating NMN, choose a product that matches the doses used in research and provides third‑party purity testing. PEPAX NMN delivers 500 mg per serving, a dose consistent with the upper range studied in human protocols, and is manufactured under rigorous quality standards to avoid contamination with undeclared compounds.

The Bottom Line on NMN and Cardiovascular Health

Preclinical evidence points to a meaningful role for NAD⁺ repletion in preserving vascular function, and early human trials confirm that oral NMN can raise NAD⁺ levels safely and improve some metabolic risk markers. However, large‑scale, long‑term studies with direct cardiovascular endpoints are still entirely lacking. For now, NMN is best understood as a promising but unproven adjunct within a heart‑healthy lifestyle — one that addresses an underlying aging mechanism but should not replace interventions whose benefit is already backed by rigorous outcome data. As the research matures, the picture of NMN and cardiovascular health will undoubtedly become clearer, but today’s evidence demands measured optimism and continued scrutiny.

---

References

1. Yoshino M, et al. "Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women." Science. 2021;372(6547):1224–1229. [Source]
2. Igarashi M, et al. "Chronic nicotinamide mononucleotide supplementation elevates blood nicotinamide adenine dinucleotide levels in healthy subjects with mild sleep disturbance." NPJ Aging. 2022;8(1):5. [Source]
3. Fukamizu Y, et al. "Effects of orally administered nicotinamide mononucleotide on clinical parameters and nicotinamide metabolite levels in healthy Japanese men." Scientific Reports. 2022;12:6134. [Source]
4. Mills KF, et al. "Long-Term Administration of Nicotinamide Mononucleotide Mitigates Age-Associated Physiological Decline in Mice." Cell Metabolism. 2016;24(6):795–806. [Source]
5. Garten A, et al. "Physiological and pathophysiological roles of NAMPT and NAD metabolism." Nature Reviews Endocrinology. 2015;11(9):535–546. [Source]

---

---